Corporate Magazine 2012 - Boehringer Ingelheim

our businessesperspectives for better health4 Scientific work in the lab requirespatience and care.5 Modern technology in the labs isessential to perform high levelscience.54many, Boehringer Ingelheim investedmore than EUR 40 million in a new researchand development for vaccines.Supply of safe and healthy food is alsogaining in importance in Asia, especiallyin China.We have therefore opened the AsianVeterinary R&D centre in Shanghai,China, where by the end of 2012 morethan 30 scientists were working on improvedvaccines for China and SoutheastAsia. Finally, R&D centres in Guadalajara,Mexico, and Tokyo, Japan, alsocontribute to our global R&D activitiesand ensure access to the important marketsof Latin America and Japan.ANIMAL HEALTH CENTRES OF EXCELLENCEWhile Boehringer IngelheimAnimal Health R&D centresin all regions conduct vaccineresearch as well asclinical and product development,a network of centresof excellence ensuresaccessibility to specialtechnology for the entireR&D organisation.These centres include genomics(Ames), immunology(Hannover), tolerabilityacceptance studies (StJoseph) and pharmaceuticalproduct development(Ingelheim).Front line research103